Ivonescimab and chemotherapy for colorectal cancer that spread only to the liver
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called ivonescimab combined with chemotherapy for people whose colorectal cancer has spread only to the liver and cannot be surgically removed right away. The goal is to see if this combination can shrink the tumors enough to allow surgery or other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have colorectal cancer that has spread only to your liver (tiny spots elsewhere may be okay as long as they are not confirmed as cancer).
- You have not had any prior chemotherapy or other treatments for your metastatic cancer, or if you had treatment before, it ended at least 6 months ago.
- Your liver tumors are considered too large or located in a way that they cannot be safely removed by surgery right now.
- You are generally well enough to be up and about (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) plus another drug (Bevacizumab) and chemotherapy (CAPEOX) for people with colorectal cancer that has spread to the liver. The goal is to shrink the tumors enough to allow surgery to remove them.
This trial tests a new drug called ivonescimab combined with chemotherapy for people with metastatic colorectal cancer that has not spread to the liver. The goal is to see if this combination can help control the cancer better than chemotherapy alone.
This study tests a new drug (ivosimab, an immunotherapy) combined with chemotherapy given before surgery for colorectal cancer that has spread to the liver. The goal is to shrink the liver tumors to make surgery easier and improve the chance of removing all cancer.
This trial tests whether adding a new drug called ivonescimab to standard chemotherapy helps shrink advanced colon cancer before surgery. It may improve the chances of removing all the cancer and reduce the risk of it coming back.
This trial is testing a combination treatment for colorectal cancer that has spread to other parts of the body and cannot be removed with surgery. The treatment includes a drug called Ivosidenib, chemotherapy, and radiation therapy. It aims to see if this combination can help shrink or control the cancer.
This trial tests a new drug called ivonescimab, which is a bispecific antibody that targets both PD-1 and VEGF. It is for people with metastatic colorectal cancer who have already tried standard treatments and may or may not have received immunotherapy before, depending on their tumor type.
Hear when a new Colorectal Liver Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.